x

#BCSM Blog

ASBrS 2017: Oncoplastics and Adequate Margins
By: Alicia
May 8, 2017

This guest post is from Dr. Aleksandra Popadich.  Dr. Popadich came all the way to Las Vegas from New Zealand because she watched Dr. Attai’s tweets from the 2016 conference! Oncoplastic surgery is going to become a part of breast surgeon’s repertoire. The development of these skills will enable us to achieve good local control and […]

Read more ›
ASBrS 2017: Contralateral Prophylactic Mastectomy (CPM)
On: May 8, 2017
By: Alicia

ASBrS17: Contralateral Prophylactic Mastectomy (CPM) This guest post is by Dr. Diane Radford. The American Society of Breast Surgeons published a consensus statement on CPM in which it was stated that average-risk women with unilateral breast cancer do not derive any oncologic benefit from CPM, and thus CPM should be discouraged (Annals of Surgical Oncology […]

Read more ›
ASBrS 2017 Lymphedema Panel
On: May 8, 2017
By: Alicia

Thank you to Dr. Kimberli Cox for submitting this review of the Lymphedema Panel at ASBRS 2017. The panel, a multidisciplinary (breast surgeons, plastic surgeons, radiation oncology, LE therapists, PMR and our own Alicia Staley) international group presented their findings and recommendations. Stated goals were recognizing the issue, the possible lack of a definitive solution, […]

Read more ›
ASBrS 2017 – Advances in Staging
On: May 8, 2017
By: Alicia

“So, what stage am I?” This guest post is by Dr. Jaime Lewis This question and the answer helps providers and patients in understanding the extent of disease and prognosis, guiding appropriate treatment, and clustering patients in studies and guidelines. It allows us to communicate regarding groups of patients believed to be similar. The staging […]

Read more ›
Active Surveillance for DCIS – the COMET Trial

9 April 2017 On Monday April 10th we will discuss the COMET trial, which is sponsored by the Alliance cooperative group. The principal investigator is Dr. Shelley Hwang, a surgical oncologist at Duke University. This study will evaluate active surveillance for low risk DCIS. The primary objective is to evaluate the rate of ipsilateral (same […]

Read more ›